MedTrace Logo

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

NCT00351234 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether type I diabetics with carnitine deficiency exhibit increased numbers of hypoglycemic (low blood sugars) events and if unrecognized hypoglycemia occurs during continuous 72-hour glucose monitoring. If they are determined to have unrecognized hypoglycemia, then oral carnitine supplementation will be given to those subjects and they will be reassessed for the number of hypoglycemic events in a 72-hour glucose monitoring.

Conditions

Interventions

DRUG

Carnitine (drug)

Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.

Sponsors & Collaborators

  • Leadiant Biosciences, Inc.

    collaborator INDUSTRY

  • Minimed Pharmaceuticals

    collaborator INDUSTRY

  • Pharmacia/Upjohn Career Development Award

    collaborator UNKNOWN

  • Children's Mercy Hospital Kansas City

    lead OTHER

Principal Investigators

  • Larry K Midyett, MD · Children's Mercy Hospital Kansas City

Eligibility

Min Age
7 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351234 on ClinicalTrials.gov